Mechanisms of Neurotoxicity and Experimental Models

  • Diamon Gangji
  • Jerzy Hildebrand
  • Roland Gerritsen van der Hoop
Conference paper
Part of the ESO Monographs book series (ESO MONOGRAPHS)

Abstract

The mechanisms of action underlying the neurotoxicity caused by chemotherapeutic drugs can be related to the mechanism by which the drug exerts its anticancer activity, but may also be totally different. In order to be able to study these mechanisms, the development and use of in-vitro and in-vivo test models are indispensable. In addition, the models may provide a preclinical tool to test possible methods for prevention and treatment of drug-related neurotoxicity. In the first place, it can be stated that the number of available models is small, whereas most of the existing models can be strictly applied only to a specific class of anticancer drugs. Another aspect, of equal importance, is the often underestimated influence of pharmacological parameters, such as the route of administration, the kinetics of the drug and drug interactions.

Keywords

Myelin Basic Protein Cranial Irradiation Cytosine Arabinoside Vinca Alkaloid Central Nervous System Toxicity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rosenberg B: Fundamental studies with cisplatinum. Cancer 1985 (55):2303–2316PubMedCrossRefGoogle Scholar
  2. 2.
    Filipski J, Kohn KW, Bonner WM: The nature of inactivating lesions produced by platinum (II) complexes in phase lambda DNA. Chem Biol Interactions 1980 (32):321–330CrossRefGoogle Scholar
  3. 3.
    Srivastava RC, Froehlich J, Eichhorn GL: The effect of platinum binding on the structure of DNS and its function in RNA synthesis. Biochimie 1978 (60):879–891CrossRefGoogle Scholar
  4. 4.
    Stone PS, Kelman AD, Sinex FM: Specific binding of antitumour durg cis-Pt (NH3) 2C12 to DNA rich in guanine and cytosine. Nature 1974 (251):736–737PubMedCrossRefGoogle Scholar
  5. 5.
    Roberts JJ, Fravel HNA: The interaction of antitumour platinum compounds with cellular DNA in cultured cells and animal tissues: relationship to DNA cellular repair processes. Biochimie 1978 (60):869–877CrossRefGoogle Scholar
  6. 6.
    Roelofs Rl, Hrushesky W, Rogin J, Rosenberg L: Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology 1984 (34):934–938PubMedGoogle Scholar
  7. 7.
    Thompson SW, Davis LE, Kornfeld M, Hilgers RD, Standefer KJC: Cisplatin neuropathy: clinical, electrophysiological, morphologic and toxicologic studies. Cancer 1984 (54):1269–1275PubMedCrossRefGoogle Scholar
  8. 8.
    Thomas PK, Olsson Y: Connective tissue components of peripheral nerve. In: Dyck et al (eds) Peripheral Neuropathy. Saunders, Philadelphia 1984 pp 111–120Google Scholar
  9. 9.
    Terheggen PMAB, Gerritsen van der Hoop R, Floot BGJ, Gispen WH: Cellular distribution of cisdiamminedichloroplatinum (II)-DNA binding in rat dorsal root spinal ganglia: effect of the neuroprotecting peptide Org 2766. Toxicol Appl Pharmacol 1989 (99):334–343PubMedCrossRefGoogle Scholar
  10. 10.
    Muller LJ, Gerritsen van der Hoop R, Moorer-van Delft CM, Gispen WH, Roubos EW: Morphological and electrophysiological study of the effects of cisplatin in Org 2766 on rat spinal ganglion neurons. Cancer Res (in press)Google Scholar
  11. 11.
    Tomiwa K, Nolan C, Cavanagh JB: The effects of cisplatin on rat spinal ganglia: a study by light and electron microscopy and by morphometry. Acta Neuropathol 1986 (69):295–308PubMedCrossRefGoogle Scholar
  12. 12.
    Stewart D, Montpetit V, Mikhael N et al: Cisplatin neuropathy. Proc AACR 1989 (30):246Google Scholar
  13. 13.
    Stewart DJ, Wallace S, Feun L et al: A phase I study of intracarotid artery infusion of cisdiammindichloroplatinum (II) in patients with recurrent malignant intracerebral tumors. Cancer Res 1982 (42):2059–2062PubMedGoogle Scholar
  14. 14.
    Neuwelt EA, Barnett PA, Glassberg M, Frenkel EP: Pharmacology and neurotoxicity of cisdiamminedichloroplatinum, bleomycin, 5-fluorouracil and cyclophosphamide administration following osmotic blood-brain barrier modification. Cancer Res 1983 (43):5278–5285PubMedGoogle Scholar
  15. 15.
    Gormley PE, Gangji D, Wood JH, Poplack DG: Pharmacokinetic study of CNS penetration of cisdiaminedichloro platinum. Cancer Chemother Pharmacol 1981 (5):257–260PubMedCrossRefGoogle Scholar
  16. 16.
    De Koning P, Neijt JP, Jennekens FGI, Gispen WH: Evaluation of Cis-Diamminedichloroplatinum (II) (cisplatin) neurotoxicity in rats. Toxicol Appl Pharmacol 1987 (89):81–87PubMedCrossRefGoogle Scholar
  17. 17.
    Gastaut JL, Pellisier JF: Neuropathie au cisplatine: etude clinique, électrophysiologique et morphologique. Rev Neurol 1985 (141):614–626PubMedGoogle Scholar
  18. 18.
    Rebert CS, Pryor GT, Frick MS: Effects of vincristine, maytansine, and cis-platinum on behavioral and electrophysiological indices of neurotoxicity in the rat. J Appl Toxicol 1984 (4):330–338PubMedCrossRefGoogle Scholar
  19. 19.
    Gerritsen van der Hoop R, Neijt JP, Kennekens FGI, Gispen WH: Protection from cisplating induced neuropathy in rats by the ACTH (4-9) analog Org 2766. In: Pleasure D, Fiori M, Scarlato G, Scarpini E (eds) Proc. Peripheral Nerve Development and Regeneration. Livinia, Springer Verlag 1989 (19) pp 145–148Google Scholar
  20. 20.
    Gerritsen van der Hoop R: Prevention and treatment of cisplatin-induced neurotoxicity by Org 2766, and ACTH (4-9) analog. Thesis, Utrecht, 1989 pp 82–92Google Scholar
  21. 21.
    Elderson A, Gerritsen van der Hoop R, Haanstra W, Neijt JP, Gispen WH, Jennekens FGI: Vibration perception and thermoperception as quantitative measurements in the monitoring of cisplatin induced neuropathy. J Neurol Sci 1989 (93):167–174PubMedCrossRefGoogle Scholar
  22. 22.
    De Koning P, Neijt JP, Jennekens FGI, Gispen WH: Org 2766 protects from cisplatin induced neurotoxicity in rats. Exp Neurol 1988 (97):746–750CrossRefGoogle Scholar
  23. 23.
    Gerritsen van der Hoop R, De Koning P, Boven E, Neijt JP, Jennekens FGI, Gispen WH: Efficacy of the neuropeptide Org 2766 in the prevention and treatment of cisplatin-induced neurotoxicity in rats. Eur J Cancer Clin Oncol 1988 (24):637–642CrossRefGoogle Scholar
  24. 24.
    Gerritsen van der Hoop R, Vecht ChJ, Van der Burg MEL, Elderson A, Boogerd N, Hermans JJ, Vries JC, van Houwellin G, Jennekens FGI, Gispen WH, Neijt JP: Org 2766, an ACTH (4-9) analog, prevents cisplatin induced neuropathy in ovarian cancer patients. N Engl J Med 1990 (322):89–94CrossRefGoogle Scholar
  25. 25.
    Mollman, Glover J, Hogan M, Furman RE: Cis Platin Neuropathy. Risk factors, prognosis and protection by WR-2721. Cancer 1988 (61 ):2192–2195PubMedCrossRefGoogle Scholar
  26. 26.
    Hoeve LJ, Mertens zur Borg IRAM, Rodenburg M, Brocaar MP, Groen BGS: Correlation between cisplatinum dosage and toxicity in a guinea pig model. Arch Otorhinolaryngol 1988 (245):98–102PubMedCrossRefGoogle Scholar
  27. 27.
    Baranak CC, Wetmore RF, Packer RJ: Cis-platinum ototoxicity after radiation treatment: an animal model. J Neurooncol 1988 (6):261–267PubMedCrossRefGoogle Scholar
  28. 28.
    Granowetter L, Rosenstock JG, Packer RJ: Enhanced cis-platinum neurotoxicity in pediatric patients with brain tumors. J Neurooncol 1983 (1):293–297PubMedCrossRefGoogle Scholar
  29. 29.
    Wagstaff AJ, Ward A, Benfield P, Heel RC: Carboplatin: a preliminary review of its pharmacodynamics and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer. Drugs 1989 (37):162–190PubMedCrossRefGoogle Scholar
  30. 30.
    Boven E, Van Der Vijgh WSF, Nauta MM, Schluper HMM, Pinedo HM: Comparative activity and distribution studies of five platinum analogues in nude mice bearing human ovarian carcinoma xenografts. Cancer Res 1985 (45):86–90PubMedGoogle Scholar
  31. 31.
    Bhattacharyya B, Wolff J: Membrane-bound tubulin in brain and thyroid tissue. J Biol Chem 1975 (250):7639–7646PubMedGoogle Scholar
  32. 32.
    Hemminski K: Effects of colchicine and cytochalasin B on labelling and enzyme activities of brain plasma membranes. Int J Neurosci 1973 (6):159–163CrossRefGoogle Scholar
  33. 33.
    Hindelang-Gertner C, Stoeckel ME, Porte A, Stertinsky F: Colchicine effects on neurosecretory neurons and other hypothalamic and hypophysial cell, with special reference to changes in the cytoplasmic membranes. Cell Tiss Res 1976 (170):17–41CrossRefGoogle Scholar
  34. 34.
    Geraerts WPM, Ter Maat A, Vreughdehil E: The peptidergic neuroendocrine control of egg-laying behavior in Aphysia and Lymnea. In: Laufer H, Downer R (eds) Inter Vertebrate Endrocrinology. AR Liss Inc.,New York 1988 (Vol. 2) pp 141–231Google Scholar
  35. 35.
    Green LS, Donoso JA, Heller-Bettinger IE, Samson FE: Axonal transport disturbances in vincristineinduced peripheral neuropathy. Ann Neurol 1977 (1):255–262PubMedCrossRefGoogle Scholar
  36. 36.
    Goldschmidt RB, Steward O: Comparison of the neurotoxic effects of colchicine, the vinca alkaloids and other microtubule poisons. Brain Res 1989 (486):133–140PubMedCrossRefGoogle Scholar
  37. 37.
    Dustin P: Microtubules. Springer-Verlag London, Heidelberg 1978Google Scholar
  38. 38.
    Schlaepfer WW: Vincristine-induced axonal alterations in rat peripheral nerve. J Neuropathol Experim Neurol 1971 (30):488–505CrossRefGoogle Scholar
  39. 39.
    Donoso JA, Green LS, Heller-Bettinger IE, Samson FE: Action of the vinca alkaloids vincristine, vinblastine, and desacetyl vinblastine amide on axonal fibrillar organelles in vitro. Cancer Res 1977 (37):1401–1407PubMedGoogle Scholar
  40. 40.
    Muller LJ, Moorer van Delft CM, Roubos EW: Snail neurons as a possible model for testing neurotoxic side effects of antitumour agents: Paracrital formation by vinca alkaloids. Cancer Res 1988 (48):7184–7188PubMedGoogle Scholar
  41. 41.
    Menesini Chen MG, Chen JS, Calissano P, Levi Montalcini R: Nerve growth factor prevents vinblastine destructive effects on sympathetic ganglia in newborn mice. Proc Natl Acad Sci 1977 (74):5559–5563CrossRefGoogle Scholar
  42. 42.
    Owellen RJ, Owens AH, Donigan DW: The binding of vincristine, vinblastine and colchicine to tubulin. Biochem Biophys Res Commun 1972 (47):685–691PubMedCrossRefGoogle Scholar
  43. 43.
    Takasugi BJ, Jones SE, Robertone AB: Phase II trial of vinzolidine, an oral vinca alkaloid, in Hodgkin‘s disease and non-Hodgkin’s lymphoma. Cancer Treat Rep 1984 (68):1399–1401PubMedGoogle Scholar
  44. 44.
    Binet S, Fellows A, Lataste H, Krikorian A, Couzimier JP, Meininger V: In situ analysis of the action of navelbine on various types of microtubules using immunofluorescence. Semin Oncol 1989 (16):5–8PubMedGoogle Scholar
  45. 45.
    Gerzun K, Ochs S, Todd GG: Polarity of vincristine, vindasine and vinblastine in relation to neurological effects. Proc Am Assoc Cancer Res 1979 (20):46Google Scholar
  46. 46.
    Nelson RL, Dyke RW, Root MA: Comparative pharmacokinetics of vindesine, vincristine and vinblastine in patients with cancer. Cancer Treat Rev 1980 (7):17–24PubMedCrossRefGoogle Scholar
  47. 47.
    Noble RL, Gout PW, Wijcik LL, Hebden HF, Beer CT: The distribution of 3Hvinblastine in tumor and host tissues of Nb rats bearing a transplantable lymphoma which is highly sensitive to the alkaloid. Cancer Res 1977 (37):1455–1460PubMedGoogle Scholar
  48. 48.
    Jackson DV, Sethi VS, Spurr CL, McWorther JM: Pharmacokinetics of vincristine in the cerebrospinal fluid of humans. Cancer Res 1981 (41):1466–1468PubMedGoogle Scholar
  49. 49.
    Jackson DV, Castle MC, Poplack DG: Pharmacokinetics of vincristine in the cerebrospinal fluid of sub-human primates. Cancer Res 1980 (40):722–724PubMedGoogle Scholar
  50. 50.
    Gaidys WG, Dickerman JD, Walters CL, Young PC: Intrathecal vincristine: Report of a fatal case despite CNS washout. Cancer 1983 (52):799–801PubMedCrossRefGoogle Scholar
  51. 51.
    Letourneau PC, Ressler AH: Inhibition of neurite initiation and growth by taxol. J Cell Biol 1984 (98):1355–1362PubMedCrossRefGoogle Scholar
  52. 52.
    Masurovsky EB, Peterson ER, Crain SM, Horfowitz SB: Microtubule arrays in taxol treated mouse dorsal root ganglia-spinal cord cultures. Brain Res 1981 (217):392–398PubMedCrossRefGoogle Scholar
  53. 53.
    Parnass J, Horowitz SB: Taxol binds to polymerized in vitro. J Cell Biol 1981 (91):479–487CrossRefGoogle Scholar
  54. 54.
    Slotwiner P, Song SK, Anderson PJ: Spheromembrenous degeneration of muscle induced by vincristine. Arch Neurol 1966 (15):172–176PubMedGoogle Scholar
  55. 55.
    Graff GLA, Geuning C, Hildebrand J: Action de sulfate de vincristine sur le gastrocnemien du rat II. Effects indépendants de Palcaloide et de la dénervation motrice sur le métabolisme des phosphates inorganismes, organiques acidosoluble et des phosphalipides. Cr Soc Biol 1966 (162):588–593Google Scholar
  56. 56.
    Gottschalk PG, Dyck PJ, Kiely JM: Vinca alkaloid neuropathy: nerve biopsy studies in rats and in men. Neurology 1968 (18):875–882PubMedGoogle Scholar
  57. 57.
    Norido F, Finesso C, Fiorito P, Marino P et al: General toxicity and peripheral nerve alterations induced by chronic vincristine treatment in rabbit. Toxicology Appl Pharmacol 1988 (93):433–441CrossRefGoogle Scholar
  58. 58.
    Muller U, Moorer-Van Delft CM, Roubos EW: Snail neuron as a possible model for listing neurotoxic side effects of antitumor agents. Paracristal formation by vinca alkaloids. Cancer Res 1988 (48):7184–7188PubMedGoogle Scholar
  59. 59.
    Favaro G, Di Gregorio F, Panazzo C, Fiori MG: Ganglioside treatment of vincristine-induced neuropathy. An electrophysiologic study. Toxicology 1988 (49):325–329PubMedCrossRefGoogle Scholar
  60. 60.
    Hellmann K, Hutchinson GE, Henry K: Reduction of vincristine toxicity by cronasial. Cancer Chemother Pharmacol 1987 (20):21–25PubMedCrossRefGoogle Scholar
  61. 61.
    Jackson DV Jr, Rosenbaum DL, Carlisle LH, Long TR, Wells HG, Spurr CL: Glutamic acid modifications of vincristine toxicity. Cancer Biochem Biophys 1984 (7):245–252PubMedGoogle Scholar
  62. 62.
    Jackson DV, Wells HB, Atkins JN, Zekan PJ, White DR, Richards F, Gruz JM, Muss HM: Amelioration of vincristine neurotoxicity by glutamic acid. Am J Med 1988 (84):1016–1022PubMedCrossRefGoogle Scholar
  63. 63.
    Jolivet J, Cowan KH, Curt GA, Clendenin NJ, Chabner BA: The pharmacology and clinical use of methotrexate. N Engl J Med 1983 (3):1094–1104CrossRefGoogle Scholar
  64. 64.
    Chabner BA, Allegra CJ, Curt GA, Clendeninn NJ, Baram J, Koizumi S, Drake JC, Jolivet J: Polyglutamation of methotrexate. J Clin Invest 1985 (76):907–912PubMedCrossRefGoogle Scholar
  65. 65.
    Pinedo HM, Chabner BA: Role of drug concentration, duration of exposure and endogenous metabolites in determining methotrexate cytotoxicity. Cancer Treat Rep 1977 (61):709–715PubMedGoogle Scholar
  66. 66.
    Gangji D, Ducore J, Poplack D, Kohn K, Glaubiger D: Concentration and time dependance of methotrexate cytotoxicity in mouse L1210 leukemia cells and human Burkitt’s lymphoma cells. Clin Res 1980 (28):525Google Scholar
  67. 67.
    Goldie JH, Price LA, Harrap KR: Methotrexate toxicity: correlation with duration of administration, plasma level doses and excretion pattern. Eur J Cancer 1972 (8):409–414PubMedCrossRefGoogle Scholar
  68. 68.
    Ackland SD, Schilsky RL: High-dose methotrexate: a critical reappraisal. J Clin Oncol 1987 (5):2017–2031PubMedGoogle Scholar
  69. 69.
    Bleyer WA: Neurological sequelae of methotrexate and ionising. A new classification. Cancer Treat Rep 1981 (65):89–98PubMedGoogle Scholar
  70. 70.
    Price RA, Jamieson PA: The central nervous system in childhood leukemia. II subacute leukoencephalopathy. Cancer 1975 (35):306–318PubMedCrossRefGoogle Scholar
  71. 71.
    Rubinstein LJ, Herman MM, Long TF, Wilbur JR: Disseminated necrotizing leukoencephalopathy: a complication of treated central nervous system leukemia and lymphoma. Cancer 1975 (35):291–305PubMedCrossRefGoogle Scholar
  72. 72.
    Gangji D, Reaman GH, Cohen SR, Bleyer WA, Poplack DG: Leukoencephalopathy and elevated levels of myelin basic protein in the cerebrospinal fluid of patients with acute lymphoblastic leukemia. N Engl J Med 1980 (303): 19–21PubMedCrossRefGoogle Scholar
  73. 73.
    Price RA: Therapy related central nervous system diseases in children with acute lymphocytic leukemia. In: Mastrangelo R, Poplack DG, Riccardi R (eds) Central Nervous system Leukemia Prevention and Treatment. Martinus Nijhof, Boston 1983 pp 71–83CrossRefGoogle Scholar
  74. 74.
    Allen JC, Rosen G, Metha BM: Leucoencephalopathy following high-dose IV methotrexate with leucovorin rescue. Cancer Treat Rep 1980 (64):1261 -1273PubMedGoogle Scholar
  75. 75.
    Neijstrom E, Gabriel DA: High-dose methotrexateinduced neurotoxicity associated with elevation of CSF myelin basic protein. J Clin Oncol 1985 (3):593–594PubMedGoogle Scholar
  76. 76.
    Yap H, Blumenshein GR, Yap BS: High-dose methotrexate for advanced breast cancer. Cancer Treat Rep 1979 (63):757–761PubMedGoogle Scholar
  77. 77.
    Wernick R, Smith: Central nervous system toxicity associated with weekly low-dose methotrexate treatment. Arthritis Rheum 1989 (32):770–775PubMedCrossRefGoogle Scholar
  78. 78.
    Geieser CF, Bishop Y, Jaffe N, Furman L, Traggis D, Frei E: Adverse effects of intrathecal methotrexate in children with acute leukemia in remission. Blood 1975 (45):189–195Google Scholar
  79. 79.
    Nathan PW, Sears TA: Action of methylhydroxybenzoate on nervous conduction. Nature 1961 (192):668–669PubMedCrossRefGoogle Scholar
  80. 80.
    Hahn AF, Feasby TE, Gilbert JJ: Paraparesis following intrathecal chemotherapy. Neurology 1983 (33):1032–1038PubMedGoogle Scholar
  81. 81.
    Dutera MJ, Bleyer WA, Pomeroy TC, Leventhal C, Leventhal BG: Irradiation, methotrexate toxicity and the treatment of meningeal leukemia. Lancet 1971 (1):703–772Google Scholar
  82. 82.
    Bleyer WA, Drake JC, Chabner BA: Neurotoxicity and elevated cerebrospinal fluid methotrexate concentration in meningeal leukemia. N Engl J Med 1973 (289):770–773 PubMedCrossRefGoogle Scholar
  83. 83.
    Bleyer WA, Poplack DG, Simon RM: Concentration x time methotrexate via a subcutaneous reservoir: a less toxic regimen for intraventricular chemotherapy of central nervous system neoplasms. Blood 1978 (51):835–842PubMedGoogle Scholar
  84. 84.
    Bleyer WA, Savitch JL, Holcenberg JS: An improved regimen for intrathecal chemotherapy. Clin Pharmacol Exp Ther 1976 (19):103–104Google Scholar
  85. 85.
    Dufner PK, Cohen ME, Brecher ML, Berer D, Parthasarathy KL, Bakshi S, Ettinger LF, Freeman A: CT abnormalities and altered methotrexate clearances in children with CNS leukemia. Neurology 1984 (34):229–233Google Scholar
  86. 86.
    Morse M, Savitch J, Balis F, Miser J, Feusner J, Reaman G, Poplack DG, Bleyer AW: Altered central nervous system pharmacology of methotrexate in childhood leukemia: Another sign of meningeal relapse. J Clin Oncol 1985 (3):19–24PubMedGoogle Scholar
  87. 87.
    Grossman SA, Chen DCP, Thompson G: Cerebrospinal fluid abnormalities in patients with the neoplastic meningitis. An evaluation using “indium-DTPA ventriculography”. Am J Med 1982 (73):641–647PubMedCrossRefGoogle Scholar
  88. 88.
    Lampkin BC, Higgins GR, Hammond D: Absence of neurotoxicity following massive intrathecal administration of methotrexate. Cancer 1967 (20):1780–1781PubMedCrossRefGoogle Scholar
  89. 89.
    Bates SE, Raphaelson Ml, Price RA, McKeever P, Cohen S, Poplack DG: Ascending myelopathy after chemotherapy for central nervous system acute lymphoblastic leukemia: Correlation with cerebrospinal fluid myelin basic protein. Med Ped Oncol 1985 (13):4–8CrossRefGoogle Scholar
  90. 90.
    Ochs JJ, Berger P, Brecher ML, Sinks LF, Kinkel W, Freeman Al: Computed tomography brain scans in children with acute lymphocytic leukemia receiving methotrexate alone as central nervous system prophylaxis. Cancer 1980 (45):2274–22PubMedCrossRefGoogle Scholar
  91. 91.
    Shapiro WR, Chernik NL, Posner JB: Necrotizing encephalopathy following intraventricular instillation of methotrexate. Arch Neurol 1973 (28):96–102PubMedGoogle Scholar
  92. 92.
    Yanovski JA, Packer RJ, Levine JD, Davidson TL, Micalizzi M, D’Angio G: An animal model to detect the neuropsychological toxicity of anticancer agents. Med Ped Oncol 1989 (17):216–221CrossRefGoogle Scholar
  93. 93.
    Griffin TW, Rasey JS, Bleyer WA: The effect of photon irradiation on blood-brain permeability to methotrexate in mice. Cancer 1977 (40):1109–1113PubMedCrossRefGoogle Scholar
  94. 94.
    Kamen BA, Moulder JE, Kun LE, Ring LE, Adams SM, Fish BL, Holcenberg JS: Effects of single dose and fractionated cranial irradiation on rat brain accumulation of methotrexate. Cancer Res 1984 (44):5092–5094PubMedGoogle Scholar
  95. 95.
    Veninga TS, Dankert J, Ebels EJ, Fidler VJ: Early transient accumulation of methotrexate in the cerebrospinal fluid. Act Radiol Oncol 1984 (23):69–73CrossRefGoogle Scholar
  96. 96.
    Taylor EM, Geyer JR, Milstein JM, Shaw CM, Gerac JP, Wotton P, Hubbard BA, Bleyer AW: Rodent model of chemoradiotherapy-induced white matter necrosis. NCI Monograph 1988 (6):59–64Google Scholar
  97. 97.
    van der Kogel AJ, Sissingh HA: Effects of intrathecal methotrexate and cytosine arabinoside on the radiation tolerance of the rat spinal cord. Radiother and Oncol 1985 (4):239–254CrossRefGoogle Scholar
  98. 98.
    Suzuki K, Takemura T, Okeda R, Hatakeyama S: Vascular changes of methotrexate-related disseminated necrotizing leukoencephalopathy. Acta Neuropathol 1984 (65):145–149PubMedCrossRefGoogle Scholar
  99. 99.
    Lampert PW, Tom Ml, Rider WD: Disseminated demyelination of the brain following Co 60 (gamma) radiation. Arch Pathol 1959 (68):322–330PubMedGoogle Scholar
  100. 100.
    Gilbert MR, Harding BL, Grossman SA: Methotrexate neurotoxicity: in vitro studies using cerebellar explants from rats. Cancer Res 1989 (49):2502–2505PubMedGoogle Scholar
  101. 101.
    Grossman SA, Reinhard CS: The intracerebral penetration of intraventricularly administered chemotherapeutic agents: a quantitative autoradiographic study. Proc Amer Assoc Cancer Res 1985 (26):923Google Scholar
  102. 102.
    Burch PA, Grossman SA, Reinhard CS: Spinal cord penetration of intrathecally administered cytarabine and methotrexate a quantitative audiographic study. J Natl Cancer Inst 1988 (80):1211–1216PubMedCrossRefGoogle Scholar
  103. 103.
    Royds JA, Lilleyman JS, Timperley WR, Taylor CB: Cerebrospinal fluid enolase isoenzymes and neurotoxicity in early treatment of lymphoblastic leukemia. Archives of Dis Child 1984 (59):266–269CrossRefGoogle Scholar
  104. 104.
    Abelson HT: Methotrexate and central nervous system toxicity. Cancer Treat Rep 1978 (62):1999–2001PubMedGoogle Scholar
  105. 105.
    Winick NJ, Kamen BA, Balis FM, Holcenberg J, Lester CM, Poplack DG: Folate and methotrexate polyglutamate tissue levels in rhesus monkeys following chronic low-dose methotrexate. Cancer Drug Delivery 1987 (4):25–31PubMedCrossRefGoogle Scholar
  106. 106.
    Kamen BA: Methotrexate, folate and the brain. Neurotoxicol 1986 (7):209–216Google Scholar
  107. 107.
    Duch DS, Lee CL, Edelstein MD, Nichol CA: Biosynthesis of tetrahydrobiopterin in the presence of dihydrofolate reductase inhibitors. Molec Pharmacol 1983 (24):103–108Google Scholar
  108. 108.
    Johnston MV, Silverstein FS, Greenberg M, Knutsen CA, Chandler W, Phillips T, Ensminger WD: Effects of intraventricular methotrexate on cerebrospinal fluid monoamine metabolites in rhesus monkeys. Cancer Treat Rep 1986 (70):1205–1209PubMedGoogle Scholar
  109. 109.
    Silverstein FS, Hutchinson RJ, Johnston MV: Cerebrospinal fluid biogenic amine metabolites in children during treatment for acute lymphocytic leukemia. Pediatr Res 1986 (20):285–291PubMedCrossRefGoogle Scholar
  110. 110.
    Phillips PC, Thaler HT, Allen JC, Rotenberg DA: High dose leucovorin reverses acute high-dose methotrexate neurotoxicity in the rat. Ann Neurol 1989 (25):365–372PubMedCrossRefGoogle Scholar
  111. 111.
    Kaminskas E, Nussey AC: Effects of methotrexate and of environmental factors on glycolysis and metabolic energy state in cultured Ehrlich ascites carcinoma cells. Cancer Res 1978 (38):2989–2996PubMedGoogle Scholar
  112. 112.
    Metha BM, Glass JP, Shapiro WR: Serum and cerebrospinal fluid distribution of 5 methyltetrahydrofolate after intravenous calcium leucovorin and intra ommaya methotrexate administation in patients with meningeal carcinomatosis. Cancer Res 1983 (43):435–538Google Scholar
  113. 113.
    Kufe DW, Spriggs DR: Biochemical and cellular pharmacology of cytosine arabinoside. Semin Oncol 1985 (12):34–38PubMedGoogle Scholar
  114. 114.
    Ho DHW: Distribution of kinase and deaminase of 1 D-arabinofuranosylcytosine in tissues of man and mouse. Cancer Res 1973 (33):2816–2820PubMedGoogle Scholar
  115. 115.
    Gottlieb D, Bradstock K, Kout J, Robertson T, Lee C, Castaldi P: The neurotoxicity of high dose arabinoside is age related. Cancer 1987 (60):1439–1441PubMedCrossRefGoogle Scholar
  116. 116.
    Hwang TL, Yung A, Esthey EM, Fields WS: Central nervous system toxicity with high dose Ara C. Neurology 1985 (35):1475–1479PubMedGoogle Scholar
  117. 117.
    Benger A, Browman GP, Wacke IR: Clinical evidence of a cumulative effect of high dose cytarabine on the cerebellum in patients with acute leukemia. Cancer Treat Rep 1981 (61):240–241Google Scholar
  118. 118.
    Damon LE, Mass R, Linker CA: The association between high-dose cytarabine neurotoxicity and renal insufficiency. J Clin Oncol 1989 (7):1563–1568PubMedGoogle Scholar
  119. 119.
    Salinsky MC, Levine R, Aubuchon JP, Schutta HS: Acute cerebellar dysfunction with high dose Ara C therapy. Cancer 1983 (51):426–429PubMedCrossRefGoogle Scholar
  120. 120.
    Winkelman MD, Hines JD: Cerebellar degeneration caused by the high-dose cytosine arabinoside: a clinicopathological study. Ann Neurol 1983 (14):520–527PubMedCrossRefGoogle Scholar
  121. 121.
    Spector R: Pharmacokinetics and metabolism of cytosine arabinoside in the central nervous system. J Pharm Exp Ther 1982 (22):1–6Google Scholar
  122. 122.
    Lopez JA, Agarival RP: Acute cerebellar toxicity after high dose cytarabine associated with CNS accumulation of its metabolite uracil arabinoside. Cancer Treat Rep 1984 (68):1309–1310PubMedGoogle Scholar
  123. 123.
    Zimm S, Collins JM, Miser J, Chatteir JD, Poplack DG: Cytosine arabinoside cerebrospinal fluid kinetics. Clin Pharm Ther 1984 (35):826–830CrossRefGoogle Scholar
  124. 124.
    Lopez JA, Nassif E, Vannicola P, Krikorian JG, Agarwal RP: Central nervous sytem pharmacokinetics of high dose cytosine arabinoside. J Neur Oncol 1985 (3):119–124CrossRefGoogle Scholar
  125. 125.
    Band PR, Golland JF, Bernard J: Treatment of central nervous system leukemia with intrathecal cytosine arabinoside. Cancer 1973 (32):744–748PubMedCrossRefGoogle Scholar
  126. 126.
    Breuer AC, Pitman SW, Dawson DM: Paraparesis following intrathecal cytosine arabinoside. Cancer 1977 (40):2817–2822PubMedCrossRefGoogle Scholar
  127. 127.
    Hwang TL, Yung WKA, Lee Y, Borit A, Fields WS: High-dose Ara-C related leucoencephalopathy. J Neuro Oncol 1986 (3):335–339CrossRefGoogle Scholar
  128. 128.
    Seil FJ, Leiman AC, Woodward WR: Cytosine arabinoside effects on cerebellum in tissue culture. Brain Res 1980 (186):393–408PubMedCrossRefGoogle Scholar
  129. 129.
    Yamamo T, Shimada M, Abe Y, Otha S, Ohno M: Destruction of external granular layer and subsequent cerebellar abnormalities. Acta Neuropathol 1983 (59):41–47CrossRefGoogle Scholar
  130. 130.
    Adlard BFP, Dobbing J, Sands J: A comparison of the effects of cytosine arabinoside and adenine arabinoside on some aspects of brain growth and development in the rat. Br J Pharmacol 1975 (54):33–39PubMedGoogle Scholar
  131. 131.
    Aguayo AL, Rome JS, Bray GM: Experimental necrosis of and arrest of proliferationof Schwann cells by cytosine arabinoside. J Neurocytol 1975 (4):663–674PubMedCrossRefGoogle Scholar
  132. 132.
    Koenig H: Production of injury to feline central nervous system with nucleic acid antimetabolites. Science 1958 (127):1238–1239PubMedCrossRefGoogle Scholar
  133. 133.
    Nand S, Messmore HL Jr, Patel R, Fischer SG, Fischer Rl: Neurotoxicity associated with high dose cytosine arabinoside. J Clin Oncol 1986 (4):571–575PubMedGoogle Scholar
  134. 134.
    Myers CE: The pharmacology of the fluoropyrimidines. Pharmacol Rev 1981 (33):1–15PubMedGoogle Scholar
  135. 135.
    Moertel CG, Reitemeir RJ, Bolton CF, Shorter RG: Cerebellar ataxia associated with fluorinated pyrimidine therapy. Cancer Chemother Rep 1964 (41):15–18PubMedGoogle Scholar
  136. 136.
    Lyngh HT, Droszcz CP, Albano WA, Lynch JF: Organic brain syndrome secondary to 5-fluorouracil toxicity. Dis Colon Rectum 1981 (24):130–131CrossRefGoogle Scholar
  137. 137.
    Bourk E, West CR, Chheda G, Tower DB: Kinetics of entry and distribution of 5-fluorouracil in cerebrospinal fluid and brain following intravenous injection in a primate. Cancer Res 1973 (33):1735–1745Google Scholar
  138. 138.
    Koenig H, Patel A: Biochemical basis of the acute cerebellar syndrome in 5-fluorouracil chemotherapy. Trans Am Neurol Assoc 1969 (94):290–292PubMedGoogle Scholar
  139. 139.
    Diasia RB, Beavers TL, Carpenter JT: Familial deficiency of dihydropyrimidine dehydrogenase. J Clin Invest 1988 (81):47–51CrossRefGoogle Scholar
  140. 140.
    Kuzuhara S, Ohkoshi N, Kanemarv K: Subacute leukoencephalopathy induced by carmofur, a 5-flourouracil derivative. J Neurol 1987 (234):365–370PubMedCrossRefGoogle Scholar
  141. 141.
    Okeda R, Shibutani M, Matsuo T, Kuroiwa T: Subacute neurotoxicity of 5-fluorouracil and its derivative carmofur in cats. Acta Pathol Ipn 1988 (38):1255–1266Google Scholar
  142. 142.
    Okeda R, Karakama T, Kimura S: Neuropathologic study on chronic neurotoxicity of 5-fluorouracil and its masked compound in dog. Acta Neuropathol 1984(63):334–343PubMedCrossRefGoogle Scholar
  143. 143.
    Yamamoto J, Yamashito K, Ken Ch: Effect of coadministration of uracil on the toxicity of tegafur. J Pharm Sciences 1984 (73):212–214CrossRefGoogle Scholar
  144. 144.
    Kerr G, Zimm S, Collins JM, O’Neil D, Poplack DG: Effect of intravenous dose and schedule on cerebrospinal fluid. Pharmacokinetics of 5-fluorouracil in the monkey. Cancer Res 1984 (44):4929–4932PubMedGoogle Scholar
  145. 145.
    Colvin M: The alkylating agents. In: Chabner B (ed) Pharmacologic Principles of Cancer Treatment. Saunders, Philadelphia 1982 pp 276–308Google Scholar
  146. 146.
    Pillans PI, Ponzi SF, Parker Ml: Cyclophosphamide induced DNA strand breaks in mouse embryo cephalic tissue in vivo. Carcinogenesis 1989 (10):83–85PubMedCrossRefGoogle Scholar
  147. 147.
    Colvin M: The comparative pharmacology of cyclophosphamide and ifosfamide. Semin Oncol 1982 (9):2–7PubMedGoogle Scholar
  148. 148.
    Meanwell CA, Blake AE, Kelly KA, Honigsberger L, Blackledge G: Prediction of ifosfamide/mesma associated encephalopathy. Eur J Cancer Clin Oncol 1986 (22):815–819PubMedCrossRefGoogle Scholar
  149. 149.
    Goren MR, Wright RK, Pratt CB, Horowitz ME, Dodge RK, Viar JM, Kovnar EH: Potentiation of ifosfamide neurotoxicity hematotoxicity and tubular nephrotoxicity by prior cisdiamminedichloroplatinum therapy. Cancer Res 1987 (47):1457–1460PubMedGoogle Scholar
  150. 150.
    Pratt CB, Green AA, Horowitz ME, Meyer WH, Etcubanas E, Douglas E, Kovnar E: Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna. J Clin Oncol 1986 (4):1253–1261PubMedGoogle Scholar
  151. 151.
    Lind MJ, Margison JM, Cerny T, Thatcher N, Wilkinson PM: Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma. Cancer Res 1989 (49):753–757PubMedGoogle Scholar
  152. 152.
    Goren MP, Wright RK, Pratt CB, Pell FE: Dechlorethylation of ifosfamide and neurotoxicity. Lancet 1986 (2):1219–1220PubMedCrossRefGoogle Scholar
  153. 153.
    Osborne RJ, Slevin ML: Iphosphamide, mesna and encephalopathy. Lancet 1986 (1):601Google Scholar
  154. 154.
    Heim ME, Fiene R, Schick E, Wolpert E, Queiber W: Central nervous system side effects following ifosphamide monotherapy of advanced renal carcinoma. J Cancer Res Clin Oncol 1981 (100):113–116PubMedCrossRefGoogle Scholar
  155. 155.
    Arndt CAS, Balis FM, Mc Cully CL, Colvin M, Poplack DG: Cerebrospinal fluid penetration of active metabolites of cyclophosphamide and ifosfamide in rhesus monkeys. Cancer Res 1988 (48):2113–2115PubMedGoogle Scholar
  156. 156.
    Cerny T, Castiglione M, Brunner K, Kupfer A, Martineli G, Lind G: Ifosfamide by continuous infusion to prevent encephalopathy. Lancet 1990 (335):175PubMedCrossRefGoogle Scholar
  157. 157.
    Burger PC, Kamenar E, Schold SC, Fay JW, Phillops GL, Herzig GP: Encephalomyelopathy following high-dose BCNU therapy. Cancer 1981 (48):1318–1327CrossRefGoogle Scholar
  158. 158.
    Schold SC, Fay JW: Central nervous system toxicity from high-dose treatment of systemic cancer. Neurology 1980 (30):429Google Scholar
  159. 159.
    Kleinschmidt-De Masters BK, Geier JM: Pathology of high-dose intraarterial BCNU. Surg Neurol 1989 (31):435–443CrossRefGoogle Scholar
  160. 160.
    Mahaley MS, Whaley RA, Blue M, Bertsh L: Central neurotoxicity following intracarotid BCNU chemotherapy for malignant gliomas. J Neuro Oncol 1986 (3):297–314CrossRefGoogle Scholar
  161. 161.
    Dewys WD, Fowler EH: Report of vasculitis and blindness after intracarotid injection of 1,3-bis (2 chloroethyl)-1 -nitrosurea (BCNU;NSC-409962) in dogs. Cancer Chemother Rep 1973 (57):33–40PubMedGoogle Scholar
  162. 162.
    Omojola MF, Fox AJ, Auer RN, Vinnuela FV: Hemorrhagic encephalitis produced by selective non-occlusive intracarotid BCNU injection in dogs. J Neurosurg 1982 (57)791–796PubMedCrossRefGoogle Scholar
  163. 163.
    Crafts DC, Levin VA, Nielson S: Intracarotid BCNU (NSC-409962): A toxicity study in six rhesus monkeys. Cancer Treat Rep 1976 (2):541–545Google Scholar
  164. 164.
    Goldlewski A, Szczech J: The morphology and histochemistry of adult rat neurocytes after BCNU administration. Fol Histochem Cytobiol 1985 (23):221–230Google Scholar
  165. 165.
    Godlewski A: Morphological alterations in blood vessel endothelia of rat brain after administration of CCNU. Neoplasma 1986 (33):437–445PubMedGoogle Scholar
  166. 166.
    Frytak S, Shaw JN, O’Neil BP, Lee RE, Eagan RT, Shaw EG, Richardson RL, Coles DT, Jett JR: Leukoencephalopathy in small cell lung cancer patients receiving prophylactic cranial irradiation. Am J Clin Oncol 1989 (12)27–33PubMedCrossRefGoogle Scholar
  167. 167.
    Gutin Ph, Weiss HD, Wiernik Ph, Wlaker MD: Intrathecal N, N’, Ntriethylenethiophosphoramide (thiotepa) in the treatment of malignant disease. Cancer 1976 (38):1471–1475PubMedCrossRefGoogle Scholar
  168. 168.
    Garcia JH, Sandbank U, Gutin P: Multifocal leukoencephalopathy in adult leukemia: histologic features and etiologic considerations. Acta Neuropath 1977 (40):273–276PubMedCrossRefGoogle Scholar
  169. 169.
    Strong JM, Collins JM, Lester C, Poplack DG: Pharmacokinetics of intraventricular and intravenous N, N’,Ntriethylenethiophosphoramide (thiotepa) in rhesus monkeys and humans. Cancer Res 1986 (46):6101–6104PubMedGoogle Scholar
  170. 170.
    Young RL, Ozols RF, Myers CE: The antracycline antineoplastic drugs. N Engl J Med 1981 (305):139–153PubMedCrossRefGoogle Scholar
  171. 171.
    Goormaghtight E, Ruysschaert JM: Antracycline glycoside-membrane interactions. Biochim Biophys Acta 1984 (779):271–288Google Scholar
  172. 172.
    Merker PC, Lewis MR, Walker MD, Richardson EP Jr: Neurotoxicity of adriamycin (doxorubicin) perfusion through the cerebrospinal fluid spaces of the rhesus monkey. Toxico Appl Pharmacol 1978 (44):191–205CrossRefGoogle Scholar
  173. 173.
    Siegal T, Melamed E, Sandbank V, Catane R: Early and delayed neurotoxicity of motoxantrone and doxorubicin following subarachnoid injection. J Neuro Oncol 1988 (6):135–140CrossRefGoogle Scholar
  174. 174.
    Neuwelt EA, Pagel M, Barnett P, Glassbert M, Frenkel EP: Pharmacology and toxicity of intracarotid adriamycin administration following ostmotic blood brain barrier modification. Cancer Res 1981 (41):4466–4470PubMedGoogle Scholar
  175. 175.
    Cho ES, Spencer PS, Jortner BS, Schaumburg HH: A single intravenous injection of doxorubicin induces sensory neuropathy in rats. Neurotoxicol 1980 (1):583–591Google Scholar
  176. 176.
    Cavanagh JB, Tomiwa K, Munro PMG: Nuclear and nucleolar damage in adriamycin-induced toxicity to rat sensory ganglion cells. Neuropath Appl Neurobiol 1987 (13):23–28CrossRefGoogle Scholar
  177. 177.
    Bigotte L, Olsson Y: Distribution and toxic effects of intravenously injected epirubicin on the central nervous system of the mouse. Brain 1989 (112):457–469PubMedCrossRefGoogle Scholar
  178. 178.
    Hall C, Dougherty WJ, Lebish U, Brock PG, Man A: Warning against use of intrathecal mitoxantrone. Lancet 1989(1)734PubMedCrossRefGoogle Scholar
  179. 179.
    Kondo A, Òhnish A, Nagara H, Tateishi J: Neurotoxicity in primary sensory neurons of adriamycin administered through retrograde axoplasmic transport in rats. Neuropathol Appl Neurobiol1987(13):177–192PubMedCrossRefGoogle Scholar
  180. 180.
    England JD, Asbury AK, Rhee EK, Summer AJ: Lethal retrograde axoplasmic transport of doxorubicin to motor neurons. Brain 1988 (111):915–926PubMedCrossRefGoogle Scholar
  181. 181.
    England JD, Rhee EK, Said G, Summer AJ: Schwann cell degeneration induced by doxorubicin. Brain 1988 (111):901–913PubMedCrossRefGoogle Scholar
  182. 182.
    Deliconstantinos G, Kopeikina T, Siboukidou L, Villiotou V: Evaluation of membrane fluidity effects and enzyme activities alterations in adriamycin neurotoxicity. Biochemic Pharmacol 1987 (36):1153–1161CrossRefGoogle Scholar
  183. 183.
    Kahman BD: Cyclosporine. N Engl J Med 1989 (321):1725–1738CrossRefGoogle Scholar
  184. 184.
    Atkinson K, Boland J, Britton K, Biggs J: Blood and tissue distribution of cyclosporine in humans and in mice. Transplant Proc 1983 (1):214–217Google Scholar
  185. 185.
    de Groen PC, Aksamit AJ, Rakela J, Forbes GS, From RAF: Central nervous system toxicity after liver transplantation: the role of cyclosporine and cholesterol. N Engl J Med 1987 (317):861–866PubMedCrossRefGoogle Scholar
  186. 186.
    Tollemar J, Ringeden O, Ericzon BG, Tyden G: Cyclosporine associated central nervous system toxicity. N Engl J Med 1988 (318):788–789CrossRefGoogle Scholar
  187. 187.
    Brown Z, Neild GH: Cyclosporine inhibits prostacyclin production by cultured human endothelial cells. Transplant Proc 1987 (19):1178–1180PubMedGoogle Scholar
  188. 188.
    Thompson CB, June CH, Sullivan KM, Thomas ED: Association between cyclosporine neurotoxicity and hypomagnesaemia. Lancet 1984 (11):116–120Google Scholar
  189. 189.
    Bhat BD, Meriano FV, Buchwald D: Cyclosporineassociated central nervous system toxicity. N Engl J Med 1988 (318):788CrossRefGoogle Scholar
  190. 190.
    Durrant S, Chipping PM, Palmer S, Gordon-Smith EC: Cyclosporin A, methylprednisolone and convulsions. Lancet 1982 (11):829–830CrossRefGoogle Scholar
  191. 191.
    Davenport A, Will EJ, Davison AM, Ironside JW: Toxicity of cyclosporin metabolites. Lancet 1988 (1):333CrossRefGoogle Scholar
  192. 192.
    Kunzendorf U, Brockmoller J, Jochmisen F, Keller F, Walz G, Offerman G: Cyclosporine metabolites and central nervous system toxicity. Lancet 1988 (2):1223CrossRefGoogle Scholar
  193. 193.
    Adams F, Quesada JR, Gutterman JV: Neuropsychiatry manifestations of human leukocyte interferon therapy in patients with cancer. JAMA 1984 (252):938–941PubMedCrossRefGoogle Scholar
  194. 194.
    Johnson DH, Hande KH, Hainsworth JD, Greco FA: Neurotoxicity of interferon. Cancer Treat Rep 1983 (67):958–961Google Scholar
  195. 195.
    Rohatiner AZS, Prior PF, Burton AC, Smith AT, Balkwill FR, Lister TA: Central nervous system toxicity of interferon. Br J Cancer 1983 (47):422–427CrossRefGoogle Scholar
  196. 196.
    Rosenberg SA, Lotze MT, Muul LM: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 1987 (316):889–897PubMedCrossRefGoogle Scholar
  197. 197.
    Habit DV, Lipton R, Cantell K: Interferon crosses blood-brain barrier in monkey. Proc Soc Exp Biol Med 1975 (49):287–293Google Scholar
  198. 198.
    Salazar AM, Gibb S, Gajdusek DC, Smith RA: Clinical use of interferon: central nervous system disorders. In: Came PE, Carter NA (eds) Interferon and their applications. Berlin Heidelberg Tokyo 1984 (71) pp 471–496Google Scholar
  199. 199.
    Jacobs L, O’Malley, Freemand A, Murawski J, Ekes R: Intrathecal interferon in multiple sclerosis. Arch Neurol 1982 (39):609–615PubMedGoogle Scholar
  200. 200.
    Obbens E, Feun LG, Leavens ME, Savaraj N, Stewart D, Gutterman JV: Phase I clinical trial of intralesional or intraventricular leucocyte interferon for intracranial malignancies. J Neuro Oncol 1985 (3):61–67CrossRefGoogle Scholar
  201. 201.
    Calvet MC, Gresser I: Interferon enhances the excitability of cultured neurones. Nature 1979 (278):558–560PubMedCrossRefGoogle Scholar
  202. 202.
    Merrill JE: Effects of lymphokines and monokines on glial cells in vitro and in vivo. In: Goetzl EJ, Spector NH (eds) Physiology and Diseases. AR Liss, New York 1989 pp 89–97Google Scholar
  203. 203.
    Kirchner M: Interferons, a group of multiple lymphokines. Springer Semin Immunopathol 1984 (7):347–374PubMedCrossRefGoogle Scholar
  204. 204.
    Lotze MT, Matory YL, Ettinghausen SE, Rayner AA, Sharrow SO, Seipp CA, Custer MC, Rosenberg SA: In vivo administration of purified interleukin-2. J Immunol 1985 (135):2865–2875PubMedGoogle Scholar
  205. 205.
    Byrne Gl, Lehmann L, Kirschbaum JG, Borden EC, Lee CM, Brown RR: Induction of tryptophan degradation in vitro and in vivo: a interferonstimulated activity. J Interf Res 1986 (6):389–396CrossRefGoogle Scholar
  206. 206.
    Brown RR, Lee CM, Kohler PC, Hank JA, Storer BE, Sondel PM: Altered tryptophan and neopterin metabolism in cancer patients treated with recombinant interleukin-2. Cancer Res 1989 (49):4941–4944PubMedGoogle Scholar
  207. 207.
    Elison MD, Povlishock JT, Merchant RE: Blood brain barrier dysfunction in cats following recombinant interleukin-2 infusion. Cancer Res 1987(47):5765–5770Google Scholar
  208. 208.
    Lee KY, Talpaz M, Rothberg JM, Murray JL, Papadopoulos N, Plager C, Benjamin R, Levitt D, Gutterman J: Concomitant administration of recombinant human interleukin-2 and recombinant interferon-2A in cancer patients: a phase I study. J Clin Oncol 1989 (7):1726–1732PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • Diamon Gangji
    • 1
  • Jerzy Hildebrand
    • 2
  • Roland Gerritsen van der Hoop
    • 3
  1. 1.Clinical Pharmacology and Chemotherapy UnitUniversité Libre de Bruxelles School of Medicine, Hôpital ErasmeBrusselsBelgium
  2. 2.Department of NeurologyUniversité Libre de Bruxelles School of Medicine, Hôpital ErasmeBrusselsBelgium
  3. 3.Clinical Research DepartmentDuphar BVWeespThe Netherlands

Personalised recommendations